CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA IN CHILDREN

被引:0
作者
Shutova, A. D. [1 ]
Kalinina, I. I. [2 ]
Suntsova, E., V [3 ]
Roikina, E., V [4 ]
Galstyon, G. M. [5 ]
Smetanina, N. S. [6 ]
Maschan, A. A. [7 ]
机构
[1] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Dept Haematopoiet Stem Cell Transplantat 2, Moscow 117198, Russia
[2] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Dept Pediat Hematol Oncol, Moscow 117198, Russia
[3] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Dept Hematopoiesis Depress Myeloid Leukemias Rar, Moscow 117198, Russia
[4] Dmitry Rogachev Natl Res Ctr Pediat Hematol Oncol, Mol Biol Lab, Moscow 117198, Russia
[5] Natl Med Res Ctr Hematol, Resuscitat & Intens Care Unit, Moscow 125167, Russia
[6] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Inst Hematol Immunol & Cell Technol, Moscow, Russia
[7] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, RAS, Moscow 125167, Russia
来源
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2023年 / 68卷 / 04期
关键词
thrombotic thrombocytopenic purpura; ADAMTS13; children; hemolytic anemia; thrombocytopenia; renal failure; infraction; stroke; CONFORMATIONAL ACTIVATION; ADAMTS13; DEFICIENCY; PATHOPHYSIOLOGY; PLASMA;
D O I
10.35754/0234-5730-2022-68-4-443-455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Congenital thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening genetic disorder characterized by recurrent episodes of microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction due to the deficiency or dysfunction of the ADAMTS13 enzyme. Despite the availability of clinical and laboratory diagnostic criteria the diagnosis remains challenging due to a wide range of diseases with similar appearance. Aim: to analyze the clinical manifestations and treatment results of identified cases of congenital TTP at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Methods. This article reviews 11 clinical cases with congenital TTP genetically confirmed or with typical clinical and laboratory signs. Results. Clinical and laboratory signs of TTP are highly variable and nonspecific, which was observed in the described cohort of patients. One of the trigger factors is often an acute respiratory viral infection, and stabilization of the disease can occur after transfusions of blood components. A delay of diagnosis can often lead not only to a delay of correct therapy, but also to the prescription of wrong therapy. The main diagnosis confirmatory method was a molecular genetic test, which was carried out in 8 cases. All patients diagnosed with congenital TTP were successfully treated with FFP therapy. Conclusion. Early diagnosis of TTP is difficult due to the lack of specific clinical manifestations and easily accessible laboratory tests.
引用
收藏
页码:443 / 455
页数:13
相关论文
共 50 条
  • [41] Challenges in the diagnosis of thrombotic thrombocytopenic purpura
    Siniard, Rance C.
    Gangaraju, Radhika
    May, Jori E.
    Marques, Marisa B.
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (11) : 861 - 869
  • [42] Thrombotic thrombocytopenic purpura: Crossing to safety
    George, James N.
    TRANSFUSION, 2022, 62 (06) : 1166 - 1170
  • [43] News in thrombotic thrombocytopenic purpura and ADAMTS13
    Joly, Berangere
    Beranger, Nicolas
    Benhamou, Ygal
    Coppo, Paul
    Veyradier, Agnes
    HEMATOLOGIE, 2021, 27 (04): : 188 - 199
  • [44] Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children
    Siddiqui, Anam
    Journeycake, Janna M.
    Borogovac, Azra
    George, James N.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (05)
  • [45] VINCRISTINE THERAPY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA
    OCONNOR, NTJ
    BRUCEJONES, P
    HILL, LF
    AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (03) : 234 - 236
  • [46] Caplacizumab for relapsing thrombotic thrombocytopenic purpura
    Kaczmarek, Veronika
    Holle, Johannes
    Astudillo, Rebekka
    Kempf, Caroline
    Baler, Philip
    Mueller, Dominik
    PEDIATRIC NEPHROLOGY, 2019, 34 (09) : 1625 - 1628
  • [47] Refractory Thrombotic Thrombocytopenic Purpura to Therapeutic Plasma Exchange
    Kiamos, Amy
    Boldig, Kimberly
    Reddy, Pramod
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [48] Membrane Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura
    Pernat, Andreja Marn
    Buturovic-Ponikvar, Jadranka
    Kovac, Janko
    Knap, Bojan
    Premru, Vladimir
    Benedik, Miha
    Varl, Janez
    Skofic, Natasa
    Gubensek, Jakob
    Kersnic, Bostjan
    Ponikvar, Rafael
    THERAPEUTIC APHERESIS AND DIALYSIS, 2009, 13 (04) : 318 - 321
  • [49] Complement activation in thrombotic thrombocytopenic purpura
    Reti, M.
    Farkas, P.
    Csuka, D.
    Razso, K.
    Schlammadinger, A.
    Udvardy, M. L.
    Madach, K.
    Domjan, G.
    Bereczki, C.
    Reusz, G. S.
    Szabo, A. J.
    Prohaszka, Z.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (05) : 791 - 798
  • [50] Caplacizumab for relapsing thrombotic thrombocytopenic purpura
    Veronika Kaczmarek
    Johannes Holle
    Rebekka Astudillo
    Caroline Kempf
    Philip Bufler
    Dominik Müller
    Pediatric Nephrology, 2019, 34 : 1625 - 1628